BACKGROUND: Pharmaceutical care in community pharmacies has been shown to improve adherence to chronic therapies. Long-term impact on clinical outcomes or medical cost savings, however, remains understudied. OBJECTIVE: To estimate the cost-effectiveness of a pharmaceutical care intervention program in Dutch community pharmacies that improved patients' adherence to lipid-lowering therapy. METHODS: An economic evaluation was performed using a time-dependent Markov model from the health care payer perspective. Participants were patients initiating lipid-lowering therapy for primary prevention (40%) or secondary prevention (60%) of cardiovascular events (CVEs). The intervention was the pharmaceutical care program MeMO (Medication Monitoring and Optimisation) in 9 community pharmacies in the Netherlands, based on continuous monitoring and optimization of lipid-lowering therapy in new patients. The follow-up period of the program was 1 year. The main outcome of the intervention program was discontinuation of lipid-lowering therapy. This outcome was extrapolated in the economic model to lifelong costs, quality of life, reductions in cardiovascular events, and incremental cost-effectiveness ratios. RESULTS: Patients in the MeMO program had a lower risk for therapy discontinuation, RR = 0.49 (0.37 to 0.66); the effectiveness was similar in primary and secondary prevention. In a cohort of 1,000 primary and secondary prevention patients, the MeMO program resulted in a reduction of 7 nonfatal strokes, 2 fatal strokes, 16 nonfatal myocardial infarctions (MIs), 7 fatal MIs, and 16 revascularizations over patients' lifetime. Additional medication, disease management, and intervention costs in the MeMO program were €411,000; the cost savings due to reduced CVEs were €443,000. The MeMO program resulted in 84 quality-adjusted life-years (QALYs) gained and net cost savings of €32,000. Clinical benefits and cost savings were highest in the secondary prevention population. CONCLUSION: Pharmaceutical care in community pharmacies can improve statin therapy adherence, resulting in better prevention of CVEs. The MeMO program resulted in considerable clinical benefits and net cost savings. Programs by community pharmacies targeted at improving adherence may provide good value for money, and health care insurers should consider reimbursing these activities.
C ardiovascular events, predominantly myocardial infarction and stroke, are a main cause of death and morbidity in most developed countries. 1 Dyslipidemia is a major risk factor for cardiovascular events (CVEs). Lipid-lowering therapy, specifically statins, have become a cornerstone of treatment for dyslipidemia due to their marked lowering of low-density lipoprotein cholesterol (LDL). 2 Indeed, statins have demonstrated considerable efficacy in reducing myocardial infarction (MI), stroke, and costly revascularization procedures. 3, 4 The clinical benefits of statin therapy are largest for secondary prevention of CVEs, that is, for patients who already experienced a CVE. 5, 6 Also, as primary prevention, statin therapy reduces the risk for CVE, although the absolute risk reduction is smaller due to the lower baseline risk in this population. 7, 8 The relative risk reduction of CVEs is around 30%, regardless of age, sex, prior history of CVEs, or other comorbid conditions, such as diabetes mellitus type 2 (DM2). 2 Contrasting with the high therapy adherence often achieved in clinical trial settings, adherence to lipid-lowering medication in real-world settings is often suboptimal, and many patients discontinue therapy. 9, 10 The promising results of clinical trials may therefore not be achieved in real-world settings. 11 Discontinuation of cardiovascular medication obviously leads to lower drug costs, but these cost savings are more than offset by increased medical costs of CVEs. 12, 13 Although novel drugs may improve cardiovascular outcomes in the future, increasing therapy adherence to currently available drugs is at least equally important to optimize therapy. 14 As a common place of interaction between patients and health care professionals, community pharmacies provide a promising setting for pharmaceutical care aimed to increase therapy adherence. In the Netherlands, the MeMO (Medication Improving Adherence to Lipid-Lowering Therapy in a Community Pharmacy Intervention Program: A Cost-Effectiveness Analysis into account all direct medical costs, including intervention costs, drug costs, medical costs, and disease management costs.
■■ Methods Model Structure
A cost-effectiveness model was built to evaluate the costs and benefits of lipid-lowering therapy. The following CVEs were monitored: nonfatal MI, fatal MI, nonfatal stroke, fatal stroke, and revascularization (either coronary artery bypass graft or percutaneous transluminal coronary angioplasty). Patients could die from cardiovascular or noncardiovascular causes. The key model driver was discontinuation of therapy, which influenced therapy effectiveness and thereby occurrence of CVEs. The comparators in the model were the MeMO program and usual care.
Three time-dependent Markov models were developed through which patients progressed. In the first model, patients entered without a history of CVEs ("primary prevention" model). Patients with a history of MI or other CVE, 5 patients with DM2, and patients from the primary prevention model who experienced a nonfatal MI entered the second model ("secondary prevention" model). A third model was developed for patients who had a history of stroke before entering the model or experienced a nonfatal stroke in the model ("secondary prevention after stroke" model). A simplified schematic of the Markov models is shown in Figure 1 .
Patient Population
In the MeMO population, the average age was 61 16, 17 Recently, the efficacy of the MeMO program in reducing discontinuation of lipid-lowering therapy was demonstrated. 18 In the Netherlands in 2008, large-scale and often mandatory generic substitution policies have been installed for many chronic medications, including lipid-lowering drugs. The ensuing competitive bidding strategies led to considerable price reductions of these generics. For example, the average list price for simvastatin 40 milligrams (mg; 30 pieces) dropped from 14.16 euros (€) in December 2007 to €0.99 one year later. 19 There have been concerns that generic substitution negatively influences therapy adherence. 20 The costs of improving adherence should be low because of the generics price drops. More recently, other policy reforms opened up the possibility for direct financial reimbursement of pharmaceutical care. Taken together, these 2 policy changes demonstrate the need for the study and evaluation of adherence improving programs in community pharmacies. 21 Potential reimbursement of pharmaceutical care interventions will partly depend on their clinical benefits and cost impact.
The purpose of this study was to determine whether a proactive pharmaceutical care intervention aimed to increase adherence to lipid-lowering medications (the MeMO program) offers good value for the money. To this purpose, a cost-effectiveness analysis was performed to estimate the short-and long-term costs and benefits from a Dutch health care payer perspective, taking 
Statin Efficacy
Large clinical trials were used to calculate statin efficacy for patients with hypercholesterolemia but without history of CVE (WOSCOPS study 8 ), patients with a history of CVE (except stroke) or DM2 (HPS study 5 ) , and patients with a history of stroke (SPARCL study 6 ). Patients' gender or age did not influence therapy efficacy, as shown by a large meta-analysis. 
Incidence Rates
For patients without a history of CVEs, the incidence of a first MI was taken from a Dutch observational study. 23 No Dutch incidence rates were available for the other CVEs; therefore, these were assumed to be proportional to those measured in the WOSCOPS trial. 8 Mortality after a first MI, 24,25 first stroke, 26, 27 or first revascularisation 28, 29 were taken from Dutch observational data and were inserted in the model age-dependent. Revascularization as a first cardiovascular event does not significantly increase the risk of subsequent cardiovascular death, all-cause death, or stroke. 30 Therefore, patients in the primary prevention model experiencing a revascularization but no MI did not progress to the secondary prevention model. For patients with a history of CVEs, a similar approach was used. Incidence rates for MI and stroke were taken from Dutch observational data, 31 and these were supplemented with data from the HPS and SPARCL trials to estimate CVE rates in the model. 5, 6 Adverse Events and Noncardiovascular Mortality Serious side effects of statins are rare. For the model, we used an incidence rate of rhabdomyolysis of 0.10 per 1,000 patientyears based on observational data registering 21 cases in 219,000 patient-years of statin use. 32 The average case fatality of rhabdomyolysis was 10% (96 out of 935 cases). 33 Myopathy was more common, with an incidence rate of 0.69 per 1,000 patient-years, based on 4,002 cases in 5.8 million patient-years of statin use. 34 Myopathy was not assumed to be fatal, but both myopathy and nonfatal rhabdomyolysis were associated with a loss in quality of life as will be described. Noncardiovascular mortality rates were based on Dutch overall population data and were age and sex specific.
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Therapy Persistence
Statin discontinuation (nonpersistence) rates were based on real-world Dutch observational data.
10 After 1 year, therapy persistence was 61.5%; after 2 years, persistence was 47.7% in primary prevention patients and 57.7% in secondary prevention patients. Persistence was assumed to remain stable thereafter, as supported by observational data with up to 10 years of follow-up. 9 Persistence in clinical trials is often higher than in the real world.
11 Indeed, persistence rates were reported to be between 80% and 90% in the clinical trials used for this model. 5, 8 Statin efficacy was therefore adjusted for the difference in persistence between trial and real-world settings. For example, in primary prevention patients after year 2, persistence was 80.6% in the WOSCOPS trial 8 and 47.7% in the real world. 10 The average statin efficacy in real-life patients was assumed to directly reflect this difference in persistence, that is, to be 59.2% (=47.7/80.6 × 100%) of the efficacy measured in the clinical trial.
Efficacy of the Pharmaceutical Care Program
The effectiveness of the intervention to prevent discontinuation of lipid-lowering therapy was measured using the MeMo pharmaceutical care program in the Netherlands. This program was based on a continuous monitoring of therapy use in patients who initiated lipid-lowering drugs. 15, 18 A detailed description of the MeMO program is provided elsewhere. 18 A total of 500 patients were included in the MeMO program, while 502 patients who received care as usual served as historical controls. One year after therapy initiation, the difference in discontinuation between the intervention and the usual care groups was significant with a hazard ratio (HR) of 0.49 (95% CI: 0.37 to 0.66). 18 In a post-hoc analysis of these data, similar efficacies were found for patients in primary prevention (HR = 0.47; 95% CI: 0.32 to 0.62) and secondary prevention (HR = 0.54; 95% CI: 0.35 to 0.73).
Costs
All direct medical costs were taken into account: intervention costs, drug costs, medical costs, and disease management costs. Time investments in the MeMO program were collected for the following activities: 1. Automatic selection of nonadherent patients and printing of medication profiles. The average duration of this action was 14 minutes per pharmacy per month. 2. Manual evaluation of medication profiles for nonadherence by pharmacists. This action took between 1 and 3 minutes per patient. 3. Contacting nonadherent patients and/or their prescribers.
These actions took between 5 and 60 minutes, with an average time investment of 15 minutes per nonadherent patient. Over a period of 3 months, in which the time investments were measured, 3,844 minutes were spent, and 418 patients were selected for intervention. These 418 patients were part of a total of 6,710 patients using lipid-lowering drugs. The average time investment per patient per year therefore was 2.3 minutes.
This time investment was assumed to be performed by pharmacists with an hourly rate of €61.17 The total intervention costs were €2.33 per screened patient treated with statins or, alternatively calculated, €36.80 per patient selected for intervention. Start-up costs, such as costs for training sessions, were not taken into account, since these differed between pharmacies and could not be estimated on a per-patient basis.
The average drug costs, including pharmacists' prescription fees, per defined daily dose (DDD) in the Netherlands in 2012 36 were applied to the distribution of drugs used in the MeMO program, 18 shown in Table 1 . The most used lipid-lowering drug was simvastatin (83.2%). Use of nonstatin lipid-lowering drugs was rare (1.8%). Medical costs for CVEs were based on Dutch data and were inflated to 2012 prices using the Dutch consumer price index; the costs were differentiated into costs for the first year and annual costs thereafter. 37 Disease management costs included general practitioner (GP) visits at €106 per year and laboratory tests at €26 per year. 38 Similar to another cost-effectiveness study of statin therapy, 38 patients who had discontinued statin therapy did not accrue drug costs but still used 50% of GP visits and 100% of laboratory tests.
Reliable Dutch data on productivity losses after CVEs are scarce. Therefore, indirect nonmedical costs (productivity losses) could not be taken into account in the base-case analysis. Still, strong economic, clinical, and social arguments exist to support cardiac rehabilitation and returning to work for patients suffering from a CVE. 39 Some assumptions could be made on employment and return-to-work rates based on international data as summarized in Table 2 . [40] [41] [42] All persons were assumed to retire at age 65. In a separate analysis, an estimate was made of the potential impact of productivity gains of the MeMO program.
Utilities Cardiovascular disease has a large impact on patients' healthrelated quality of life (HRQoL). This was reflected in the model by taking into account the health-related utilities of the various health-states, ranging from 1 (perfect health) to 0 (death). Patients' utilities were assumed to decrease with age, based on results from a large United Kingdom sample interviewed with the EQ-5D questionnaire. 43 The relationship between age and utility was described as follows: utility = 1.060-0.004 × age. 44 After a CVE, patients in the model incurred a disutility, based on data of the Dutch national burden of disease study. [45] [46] [47] After an MI or stroke, the disutility was 0.288 and 0.609, respectively. No disutility was assumed after revascularization. In case of joint health-states (such as MI in poststroke patients), only the largest of the 2 disutilities was applied. 48, 49 For patients with DM2, an additional disutility of 0.198 was applied. [45] [46] [47] No disutility from taking a pill everyday was assumed in the model. 50, 51 In the rare case of nonfatal rhabdomyolysis or myopathy, disutility of 0.530 was applied for 1 year. 52 Utilities and life expectancies were multiplied to calculate qualityadjusted life years (QALYs).
Cost-Effectiveness Analysis
In the cost-effectiveness analysis, the costs and clinical benefits of the MeMO program were compared with usual care. The incremental cost-effectiveness ratio (ICER) can be calculated as:
where C equals the costs and E the clinical benefits (in QALYs) of the MeMO and usual care groups. Cohorts of 1,000 patients entered the model. The time-horizon for analysis was lifelong years in the base-case; shorter time-horizons were used in sensitivity analyses. Costs and clinical effects were discounted at 4.0% and 1.5% per annum, respectively, following Dutch guidelines.
Sensitivity Analyses
An overview of all model parameters that were varied in sensitivity analyses is shown in Table 3 . For brevity, statin effectiveness and incidence rates for the nonfatal and fatal events or for noncardiovascular death are not shown in the table. In univariate sensitivity analyses, parameters were varied by 25% to determine the main cost-effectiveness drivers. Scenario analyses were performed varying the duration of the program, the costs of the intervention, and the baseline risk for vascular disease in patients without a history of CVEs. In probabilistic sensitivity analyses (PSA), 10,000 random samples were drawn from all parameters according to the specified distributions and confidence intervals shown in 
Summary of Model Parameters Varied in Sensitivity Analyses
the literature. Using the PSA, 95% CIs around the model results and the probability of the MeMO program to be cost saving or cost-effective could be calculated.
■■ Results
Statin Adherence
After 1 year in the model, 38.5% of the control patients discontinued statin therapy compared with 19.0% in the interventions group; after 2 years, statin discontinuation was 47.7% versus 23.3%, respectively.
CVE Occurrence
Occurrence of CVEs is summarized in Figure 2 . Over the total time-period of the model, a total of 7 nonfatal strokes (95% CI: 2.8 to 14.0), 2 fatal strokes (95% CI: 0.2 to 4.4), 16 nonfatal MIs (95% CI: 8.5 to 25.6), 7 fatal MIs (95% CI: 2.9 to 12.5), and 16 revascularizations (95% CI: 8.9 to 26.5) were prevented in the intervention group compared with the control group. The average life expectancy in this cohort was 81.3 years in the control group; the increase in average life expectancy in the intervention group was 48 days (95% CI: 28 to 97).
Costs and Cost-Effectiveness
In the first 5 years of the model, the increased statin use in the intervention group led to additional drug costs of €61 per patient, spread over these 5 years. In addition, a similar increase in disease management costs was estimated of €53 per patient, spread over 5 years. The average costs required for the pharmacist intervention were €7.70 per patient, spread over the first 5 years. These additional costs were more than offset by lower medical costs due to prevented CVEs, leading to an average cost savings of €126 per patient over the first 5 years of the model.
The cost-effectiveness of the MeMO program over patients' lifetime is summarized in Table 4 . Increasing statin adherence with the MeMO program was a dominating strategy in the overall patient population. The majority of cost savings were due to CVE prevention in the secondary prevention population. Still, the MeMO intervention was highly cost-effective (€4,585 per QALY gained) in primary prevention.
Sensitivity Analyses
All model parameters described in Table 3 were subjected to univariate sensitivity analyses. The only parameters resulting, driver. The program led to cost savings even if intervention costs were doubled. In the primary prevention population, the 10-year risk for CVEs was 4.8%. In patients with a higher risk for CVEs, the cost savings and clinical benefits increased, shown in Figure 4 . Table 5 summarizes permanent and temporary loss of work because of CVEs in cohorts aged 40, 50, or 60 years. As all patients were assumed to retire at age 65, the productivity gains from the MeMO program were higher for younger patients than for older patients. Around 40%-45% of permanently lost jobs were full-time jobs; around 50%-60% of temporary lost jobs were full-time jobs. The average absent time for persons temporarily out of work was 50 days.
CVEs Prevented in the MeMO
Work Productivity
■■ Discussion Principal Findings
This study assessed the cost-effectiveness of a community pharmacy intervention program aimed to improve adherence to statin therapy by preventing discontinuation for both primary and secondary prevention patients. Improvements in therapy use were extrapolated to lifetime reductions in cardiovascular events, cost savings, and quality-of-life gains. Based on the model's results, the intervention was a dominating strategy (net cost savings and clinical benefits) compared when changed by 25%, in a positive ICER were a higher age (€1,866 per QALY), a lower statin effectiveness (€1,289 per QALY), or lower CVE incidence (€905 per QALY). The 15 most influential factors for net cost savings and QALY gains are shown in Figure 3 . Probabilistic sensitivity analyses showed that the probability of cost savings of the MeMo program was 60.7%. The probability of being cost-effective at the common willingness-to-pay thresholds of €20,000 or €50,000 per QALY gained was 100%. In the primary prevention population, there was a low (5.3%) probability of cost savings, but a 91.7% and 98.1% probability for cost-effectiveness at the above mentioned thresholds. In the secondary prevention population, there was a very high (94.1%) probability for net cost savings and a 100% probability of cost-effectiveness.
Scenario Analyses
The cost savings and health gains decreased with more pessimistic assumptions on the durability of the effectiveness of the intervention. tion. Although several studies assessed the cost-effectiveness of statin therapy, and some included the level of adherence as a model parameter, 38 none specifically assessed the costeffectiveness of improving adherence to statin therapy.
Some health economic analyses of statins included a small but measurable disutility from taking a statin pill every day. 38, 58 Other studies, however, did not 44, 59 or only applied a disutility in sensitivity analyses. 60, 61 The studies that included a disutility for statin use based this on assumption 58 or on analogy to models in aspirin or warfarin. 38 Long-term follow-up studies, however, have found no influence of statin use on quality of life.
50,51 Therefore, we included no disutility for chronic statin use apart from disutilities arising from possible side effects.
Implications for Pharmacists and Policymakers
The results of our study suggest that it would be cost-effective to promote and reimburse pharmacy-led interventions to improve statin therapy adherence. The costs of pharmacist intervention was low compared with standard disease management costs. This has also been reported for other adherenceimproving programs. 57 Compared with these other programs, the per-patient costs of this intervention were also relatively low. This is because in the MeMO intervention patients are monitored with semiautomated procedures, and only nonadherent patients are selected for the more time-consuming personal counseling. Such targeted approaches lead to more efficient pharmaceutical care programs. 21 Scenario analyses show that apart from medical cost savings, considerable productivity gains may also be achieved by the intervention, especially in younger persons.
Future Research
As with most pharmacoeconomic analyses, several assumptions had to be made. The most important of which was the extrapolation of the short-term follow-up period of the MeMO intervention to lifelong costs and CVEs. Future research should continue to monitor adherence-improving programs and ideally directly measure the clinical benefits of such programs. However, as time constraints and costs may be prohibitive for such studies, cost-effectiveness modeling efforts such as this study should provide valuable information on the potential value of adherenceimproving programs in community pharmacies.
■■ Conclusion
Pharmaceutical care in community pharmacies can improve statin therapy adherence, resulting in more optimal prevention of CVEs. The MeMO program resulted in considerable clinical benefits and overall cost savings. Adherence-improving programs in community pharmacies may provide good value for money, and health care insurers should consider reimbursing these activities in the Netherlands.
with usual care. The benefits of the intervention were largest in patients with DM2 or a history of CVEs, but the program was also cost-effective for patients receiving statins for primary prevention.
Limitations
To our knowledge, this is the first pharmacoeconomic analysis of statin therapy to model primary as well as secondary prevention patients. The model was quality checked by an author not involved in model building using a standardized checklist 53 as well as a thorough check of all model calculations. The effectiveness of the MeMO program was based on a large community pharmacy program. 18 A limitation of this program was that clinical parameters (such as LDL levels) were not measured. Several important assumptions were made in this cost-effectiveness model. An important assumption was that the effect of the intervention program would last throughout the patients' lifetime. If the duration of effectiveness of the intervention was reduced in scenario analyses, the cost savings and clinical benefits decreased accordingly. Still, even with a 1-year duration of effectiveness, the intervention was cost saving strategy albeit with fewer QALY gains. The model also assumes similar efficacy for the different lipid-lowering drugs, which may not be true. 23, 54, 55 Finally, the assumption was made that adherent patients could achieve the efficacy measured in clinical trials at a dose equivalent of 1 DDD (this unit is the average daily dose of a drug for its main indication in adults and is recommended by the World Health Organization). The actual DDD equivalents prescribed in the Dutch setting varied per drug but was close to 1 for the most commonly prescribed simvastatin (1.02 ± 0.39).
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Comparison with Other Studies
Few studies have assessed the costs and effectiveness of adherence-improving interventions for lipid-lowering drugs. 57 The most effective of these interventions were those where adherence is closely monitored, similar to the MeMO interven- 
